Capital Ii Lpaisling Capita... Net Worth

The estimated Net Worth of Capital Ii Lpaisling Capita... is at least $61.2 million dollars as of 22 October 2013. Capital Capita owns over 411,765 units of Adma Biologics Inc stock worth over $61,216,618 and over the last 11 years Capital sold ADMA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Capita ADMA stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Adma Biologics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Capital bought 411,765 units of ADMA stock worth $3,500,003 on 22 October 2013.

The largest trade Capital's ever made was buying 411,765 units of Adma Biologics Inc stock on 22 October 2013 worth over $3,500,003. On average, Capital trades about 411,765 units every 0 days since 2013. As of 22 October 2013 Capital still owns at least 3,620,143 units of Adma Biologics Inc stock.

You can see the complete history of Capital Capita stock trades at the bottom of the page.

Insiders trading at Adma Biologics Inc

Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ... et Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.

What does Adma Biologics Inc do?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Complete history of Capital Capita stock trades at Adma Biologics Inc

Adma Biologics Inc executives and stock owners

Adma Biologics Inc executives and other stock owners filed with the SEC include:

• Adam Grossman,
  President, Chief Executive Officer, Co-Founder, Director
• James Mond,
  Executive Vice President, Chief Scientific Officer, Chief Medical Officer
• Adam S. Grossman,
  Co-Founder, Pres, CEO & Director
• Brian Lenz,
  Chief Financial Officer, Executive Vice President
• Dr. James Mond,
  Exec. VP, Chief Scientific Officer & Chief Medical Officer
• Brian Lenz CPA, CPA,
  Exec. VP, CFO & GM of ADMA BioCenters
• Jerrold Grossman,
  Vice Chairman of the Board, Co-Founder
• Steven Elms,
  Independent Chairman of the Board
• Bryant Fong,
  Independent Director
• Lawrence Guiheen,
  Independent Director
• Dr. Jerrold B. Grossman D.P.S., Ph.D.,
  Co-Founder & Vice Chairman
• Dr. Jerrold B. Grossman Ph.D., D.P.S.,
  Co-Founder & Vice Chairman
• Martha Demski,
  Independent Director
• Cyndi Tolman,
  Sr. VP of Plasma Services
• Neal C. Fitzpatrick,
  VP of Sales
• Michael Goldstein,
  Sr. Director & Gen. Counsel
• Dr. Gene A. Wetzstein BCOP, Pharm.D.,
  Exec. Director & Head of Scientific Engagement
• Drew Pantello,
  VP of Marketing & Corp. Devel.
• Michael Least,
  VP of Sales & Commercial Operations
• Kaitlin Kestenberg,
  VP of Compliance, Project Management & Clinical Operations
• Skyler Bloom,
  Director of Investor Relations & Corp. Strategy
• Kim Tripodo,
  Exec. Director & Head of Human Resource and Admin. Operations
• Eric I Richman,
  Director
• Dov A Md Goldstein,
  Director
• Ag Biotest Pharmaceuticals ...,
  
• Young Kwon,
  
• Alison Cecily Finger,
  
• Divestiture Trust Biotest,
  10% owner
• Steve Elms,
  
• Advisors Llcperceptive Life...,
  
• Brad L. Tade,
  CFO and Treasurer
• Kaitlin M. Kestenberg Messina,
  COO and SVP, Compliance